{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-008131","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.901466+00:00","generated_at":"2026-05-26T03:12:53.490076+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M","bullets":["Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).","FY net income $141.2M ($1.23 diluted EPS) vs $106.1M ($0.94) in 2023.","2025 revenue guidance $900-$950M; cash and investments $603.2M at Dec 31, 2024.","NDA submitted for relacorilant for hypercortisolism; ROSELLA Phase 3 data expected this quarter.","DAZALS Phase 2 in ALS missed primary endpoint; showed survival benefit (0 vs 5 deaths at 24 weeks, p=0.02)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-008131","json":"https://secwatch.observer/filing/0001628280-25-008131.json","markdown":"https://secwatch.observer/filing/0001628280-25-008131.md","text":"https://secwatch.observer/filing/0001628280-25-008131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828025008131/0001628280-25-008131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828025008131/cort-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:12:53.490076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}